Tadalafil and Bosentan on pulmonary arterial pressure, cardiac outupt and prognosis of mechanical ventilation in COPD patients with pulmonary hypertenion under mechanical ventilation

Evaluation efficacy of Tadalafil and Bosentan on pulmonary arterial pressure, cardiac outupt and prognosis of mechanical ventilation in COPD patients with pulmonary hypertenion under mechanical ventilation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190325043107N24

Enrollment

100

Registered

2021-10-14

Start date

2021-11-21

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: Intervention group 1: Patients will be treated with the available drugs for three weeks, so that patients in the Bosentan group will receive 125 mg of the drug twice a day. Intervent

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: History of COPD Hospitalized in the pulmonary intensive care unit Under controlled breathing or connected to a ventilator

Exclusion criteria

Exclusion criteria: Body mass index higher than 30 Lung cancer and any other type of cancer Right and left ventricular dysfunction Chest radiotherapy during the last month

Design outcomes

Primary

Measure	Time frame
Pulmonary function. Timepoint: Once every three days for three weeks. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Pishbin

Tabriz University of Medical Sciences

Pishbin@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026